Open AccessIn Vitro and In Vivo Test of Boron Delivery Agent for BNCT
Author(s) -
Sista Dyah Wijaya,
Bagaswoto Poedjomartono,
Yohannes Sardjono
Publication year - 2019
Publication title -
indonesian journal of physics and nuclear applications
Language(s) - English
Resource type - Journals
eISSN - 2550-0570
pISSN - 2549-046X
DOI - 10.24246/ijpna.v4i2.39-44
Subject(s) - boron , in vivo , neutron capture , radiochemistry , in vitro , delivery system , materials science , chemistry , medicine , pharmacology , biochemistry , organic chemistry , biology , microbiology and biotechnology
BNCT is an alternate therapy for treating cancer. The principle of BNCT involves a neutron boron uptake and a fission reaction that produce alpha particles and Li ions with a high level of linear energy transfer in the tissue. It is effective in killing tumor cells. To administer boron in the tumor cells, a boron delivery agent is needed. Thus far, there are a variety of boron delivery agents that have been developed. To date, just two main boron-based drugs, BPA and BSH, have been used for clinical studies. Many other boron delivery agents have been evaluated in vivo and in vitro but have not been evaluated clinically. Therefore, the other boron delivery agents have not been used in BNCT clinical studies.